Chemtura Corp.

Novel therapeutic candidates and companion diagnostic tests intended to treat various indications across precision oncology, rare diseases, autoimmune diseases, and age-related disorders Strategic partnership with PMC Group streamlines all Chemistry, Manufacturing, and Control (CMC) activities of each program Co-Founded by Dr. Raj Chakrabarti, Ph.D., Chairman and CEO of CCM Biosciences and President of PMC Group International and Dr. Anisha Ghosh, Professor of Finance at McGill University MOUNT LAUREL, N.J., Aug. 29, 2023 /PRNewswire/ -- Diversified biotechnology company CCM Biosciences launched from stealth today with more than ten drug programs, many of which originated from CCM Biosciences' proprietary drug discovery platforms. CCM Biosciences is partnered with the global chemical and pharmaceutical manufacturing company PMC Group for the Chemistry, Manufacturing, and Controls (CMC) of its drug programs. The CCM-PMC partnership offers a fully integrated ecosystem for the discovery, development, and manufacturing of drug candidates addressing some of the most significant unmet medical needs. The company has raised more than $25M in financings including Series A1 and A2 rounds at a multi-hundred million dollar valuation. Continue Reading PMC (PRNewsfoto/CCM Biosciences) Diverse Portfolio of First-in-Class Drug Candidates CCM Biosciences possesses an expansive portfolio of novel product candidates including disruptive KRAS therapeutics that target the oncogene responsible for 25% of all cancers, selective first-in-class degraders of oncogenic kinases for lung cancer and leukemia, inhibitors of the master immune regulator cGAS for autoimmune disorders, therapies for nonsense mutations that account for 10% of all genetically inherited diseases, and disruptive drug candidates for mitochondrial upregulation relevant to a host of age-related disorders such as Parkinson's, Alzheimer's, and infertility. Several of CCM Biosciences' novel drug candidates have already reached significant development milestones. Extensive validation of the drugs' scientific foundations has appeared in multiple peer-reviewed publications. Investigational New Drug applications are expected to be filed with the FDA in the near future, based on clinical trial plans developed with leading medical experts from institutions including Cleveland Clinic and Ohio State University. Dr. Sudipto Mukherjee, clinical trials investigator for CCM Biosciences' autophagy inhibitor drug program and a hematologist-oncologist at Cleveland Clinic's Taussig Cancer Institute, expressed his enthusiasm about the program saying, "CCM's program, in-licensed from Cleveland Clinic and lead optimized at CCM, has the potential to address a significant unmet need in leukemia treatment." Leadership Team with Deep Expertise in Scientific Innovation, Chemical Engineering and Finance Dr. Raj Chakrabarti (Harvard AB, Princeton PhD; formerly Professor of Chemical Engineering at Carnegie Mellon and Purdue Universities), co-founder and CEO of CCM Biosciences and President of PMC Group International, founded CCM Biosciences based on technology platforms he developed in academia in the areas of chemical biology, computational biophysics, systems biology, and synthetic biology. These platforms, which merge experimental high-throughput screening with physics-based computational methods and learning algorithms, have been responsible for the discovery of more than half of CCM Biosciences' drug candidates and all its diagnostic tests and continuously feed its pipeline of drug leads to address areas with significant unmet need. CCM's diagnostic technology platform builds off of patented technology originating in the PhD thesis work in nucleic acid polymerization and sequencing of Chakrabarti that are licensed to CCM Biosciences and are among the top 5 revenue-generating patents in the history of Princeton University, according to the university's Office of Technology Licensing. Chakrabarti's patent income as a biotechnology inventor provided $2M seed funding for CCM. Dr. Anisha Ghosh, co-founder of CCM Biosciences and Professor of Finance at McGill University, oversees the choice of drug programs comprising the company's portfolio, as well as allocation of capital among them based on modern quantitative methods for asset management, given the diversity of the company's portfolio. Ghosh's research in asset pricing and portfolio management has been published in leading journals like the Journal of Finance and Review of Financial Studies, and has been the subject of invited lectures at leading venues ranging from the National Bureau of Economic Research to the Institute for Quantitative Research in Finance. She stated: "Our cost-effective approach to reach the current stage in CCM Biosciences' lifecycle offers a unique story against the backdrop of heavily funded, albeit risky, biotech companies." PMC Group's leadership, having helmed the growth of one of the fastest-growing chemical companies in the US for over 25 years, also brings market-leading expertise in chemical manufacturing to the partnership. About CCM Biosciences CCM Biosciences is a biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, American Chemical Society journals and Nature Publishing Group iournals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, developed through acquisitions of industry-leading companies. About PMC Group PMC Group is a global chemical and pharmaceutical conglomerate, with research and manufacturing facilities spanning the US, Europe, and Asia. With revenue on the order of $1B, PMC Group has a long history of acquisitions, growth investments and operational management in the chemical and pharmaceutical industries spanning a quarter century, including acquisitions from leading global corporations such as BASF, AkzoNobel, Dow, ICI, Arkema, PPG Industries, ExxonMobil, Solvay, Chemtura, and France's SNPE. PMC has been described by the US Congress House Committee on Science and Technology as a domain leader in the US manufacturing sector alongside General Motors and Procter & Gamble. SOURCE CCM Biosciences

New York, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Filament LED Bulb Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product ; Application" - Previously, LED light sources such as COB plug patches and integrated high-power LED lamps could only be used as a plane light source in optical devices without lenses, but the LED filament broke through this barrier, and the porous metal substrate single crystal welding technology truly realized 360 degrees of solid light source, avoiding the influence of light plus lens effect and optica.Instead of using traditional blue and green phosphors to raise the brightness of the process, the blue + red chip package is used to create the conventional lighting effect and improve the light efficiency and brightness through filament LED bulbs.Additionally, compared to other LED lamps, LED filament lamps primarily use sapphire substrates and wicks instead of nonrenewable aluminium and nonbiodegradable plastic.From the present perspective, mainstream models are often just 25, 28, 32 chip packages, compared to the same number of common packages, the use of LED chip is also less, resulting in a cheaper overall cost than usual LEDs.The rising awareness about the above-mentioned benefits of filament LED bulbs across the globe through constant marketing and advertisements by manufacturers is also influencing the adoption of the same for lighting purposes, thereby contributing to the growth of the market.The customers in both developed and developing countries are highly inclined toward having aesthetically pleasing interiors at houses and commercial places; however, the COVID-19 pandemic has led to disruptions in the development of lighting systems.Furthermore, the limited availability of laborers has hampered the maintenance and rebuilding of interior infrastructure.Due to insolvency, several small cafés and eateries have closed down.The filament LED bulb market is segmented on the bases of product, application, and geography.Based on product, the market is segmented into 0-25 Watt Type, 25-40 Watt Type, 40-60 Watt Type, and Above 60 Watt Type.Based on application, the market is segmented into residential, restaurants and bars, hotels, café, and others.In terms of geography, the filament LED bulb market is broadly segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South America (SAM).In 2020, North America accounted for a significant share in the global market.Key players operating in the global filament LED bulb market include Crompton Lamps Ltd, Havells India Ltd., Wipro Consumer Lighting, MEGAMAN, OSRAM GmbH, Signify Holding (Philips), Feilo Sylvania Europe Limited, UKLED, Verbatim Americas LLC, and Seoul Semiconductor Co., Ltd., among others.The overall filament LED bulb market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.The process also serves the purpose of obtaining an overview and forecast for the filament LED bulb market with respect to all the segments.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.The participants of this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the filament LED bulb market.Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

▲限时免费参会名额倒计时🔥，1600+已报名 前   言 众所周知，海水中蕴含着无数宝藏，从而产生丰富的海水生态产业链——“初级卤水养殖、中级卤水提溴、饱和卤水制盐、苦卤提取钾镁”，为综合利用海水资源开辟了全新的发展之路。 溴产业也应运而生，成为全球战略资源发展的关键一环，目前国内溴产量占全球已经比较少了，大致只占8%，世界溴产量主要集中在美国，个别公司如雅宝、死海溴、cherries等的控制，类似产品如果从源头矿产控制掌握低成本资源，随后再往下游衍生的话可以产生比较强大的溴化物巨头。 在刚结束的3月26日晚“药鼎记”视频号的“印囧”直播中力田化学的陈总也提到过溴产业，在印度溴素价格比中国低许多，因为中国主要将溴素用在阻燃剂方面，而印度则没有做阻燃剂的工厂，因此消耗量没我国大，但是他们的产量却高于我们，因此溴资源比我们丰富，价格便会下降，因此在这溴这方面可以积极从海外源头入手，将这个作为一个核心大胆走出去，从而拓宽下游产业链，这将是一个很大的机会。 什么是溴？溴和溴产业简介 溴素，英文名：Bromine，产品别名：溴，分子式为Br2，百度百科上介绍它是一种颜色深红棕色液体，容易挥发，气温低时能冻结成固体，有着极强烈的毒害性与腐蚀性，性质很活泼，是强氧化剂，由于溴有很高的化学活性，在自然界中它主要以碱金属溴化物存在，矿物形式的溴没有工业价值，只有学术意义，可从海水中的溴化物提取，海水中只含有65ppm的溴，但是某些井卤水中溴含量却异常得高。 （图源来自“世界制溴工业概况”） 溴素主要用作制取溴化物，并用于医药、农药、染料、香料、摄影材料、灭火剂、选矿、冶金、鞣革、净水等部门用作普通分析试剂、氧化剂、乙烯和重碳氢化合物的吸收剂及有机合成的溴化剂。 溴产业是以海水、卤水、回收氢溴酸和溴化盐等为原料，进行溴产品提取、加工和其系列产品开发的行业。溴素的物化性质活泼，可以形成种类繁多的无机溴化物，也可以衍生出大量的含溴有机化合物，由于溴化物具有多种特异的物化性能，溴素也成为了用途广泛的基础化工原料，其应用领域随着上下游产品深层次不断地开发而迅速拓宽，在各行各业都发挥着日益重要的作用，特别是近代塑料工业的发展对溴系阻燃剂需求变大，禁止使用氟利昂制冷剂也使得溴化锂制冷机需求量骤增，溴行业往后市场前景广阔。 主要生产工艺与方法 （上图为溴素的生产工艺） 首先，简单说一下溴素的生产过程，溴在自然界存在主要是卤水和海水，海边盐碱地下面的卤水，相应溴的提取主要是投入废酸和铜铝，因为成本比较低。其实这样纯度还是不够，还要继续用废酸再用铜铝，直到生产过程得到99.5%的溴素。溴用蒸汽或者空气被分离出来。 目前，我国溴素生产多采用空气吹出法和水蒸气蒸馏法来制备溴素。 国内溴素近五年价格分析 2016年到2020年的全年平均价分别为25500、28500、29500、32500和29500元，虽然2020年平均价格有所回落，但是总体还是呈现上升态势，至于每年价格的最低点也是与溴的生产方式有关。 感谢昌邑华晟化学品有限公司的奚杰经理为药融圈小编提供了溴素一年中各时期价格变化的主要原因。 众所周知，因为盐溴联产的关系，所以溴的生产和晒盐分不开，在每年的7-9月份卤水晒盐的蒸发量达到最大，所以溴的产量也是达到最大，但7-9月是我国的夏季，下游化工行业受高温影响，开工率不足，因此每年溴的价格最低位往往出现在7-8月份；而到了每年的11月下旬，渤海湾一带进入冬季，晒盐的蒸发量急剧减少，海水提溴的工厂进入完全停产，地下卤水提溴的工厂也开始大幅减产，至12月下旬受环保要求进入停产，待第二年的2月中下旬恢复生产，因此，每年的12月至1月份，往往是溴素最紧张的时节，溴素价位也会达到最高点。 溴素产业链 上游产品：液氯、纯碱、硫酸、硫磺。 下游产品：溴素作为重要的精细化工原料，广泛地应用于阻燃剂、制药、制冷、电子化学品等，用途十分广泛，溴以及溴产品下游产品用途广泛，主要分为以下行业： 它是各种药用溴盐及有机溴化物的主要原料还多用于有机和无机化工的化合物制备，在医药上不仅可以用来生产抗菌素、维生素和激素中间体，常用的溴片、三溴合剂和巴甫洛夫合剂，还可以用于治神经衰弱和歇斯底里症等；农药上可以用来制造杀虫剂、植物生长激素和熏蒸剂，工业上制造燃料、香料、摄影材料、合成纤维、催泪型毒气和灭火器等等。 溴化丁基橡胶的用溴量发展十分可观，目前国内年用量约0.7万吨/年，预计至2022年用溴量估计能到达1 万吨/年。 全球产能分布 国外主要产能 目前，溴的主要制造商集中在ICL、Albemarle和Laxness。ICL是世界上最大的溴及其衍生物生产商。其他还有日本Tosoh、印度的主要厂家Archean、Agrocel以及国外其他地区的厂家。 （注：LANXESS（朗盛）溴化物部门的前身是美国的Great Lakes Chemical 。2005年，和美国康普顿公司合并为Chemtura，在2017 年被LANXESS 收购） 奚杰经理告诉药融圈小编，国内潍坊工厂在国外投资了溴化钠产能，老挝约为0.2万吨，吉布提2万吨，将它们生产的一部分溴化钠进口到国内用于提溴，目前产能约有1万吨；其次，非洲溴资源储存量巨大，但是开采、运输和配套原料等条件都有待解决，但往后陆续会有其他工厂到非洲投资溴的开采。 国外主要生产厂家 ICL ICL是是世界上最大的溴生产商，供应超过33%的全球需求。溴和以溴为基础的化合物是广泛应用于工业领域的基本成分，如热稳定剂、感光乳剂、木材防腐剂、催化剂(季铵溴化物)、烷基化剂、特殊清洁溶剂、脱脂剂等。 Albemarle美国雅保 美国雅保（Albemarlecorporation）是从事精细及特殊化工产品及销售的跨国公司，总部设在弗吉尼亚州的里士满，约有4000名员工，分布于全球38个地区，服务于100多个国家。主要业务包括聚合物化学品、精细化工产品和催化剂三大部分。在消防安全、油田钻井、制药制造、高科技清洗、水处理、食品安全等领域，雅保公司的溴化产品发挥着领先的作用。同时他们也正在不断开发溴产品减少汞排放从而保护环境。 Lanxess朗盛 朗盛是全球领先的特殊化学品公司，总部位于科隆。朗盛在全球拥有约14,400名员工，分布在33个国家，在全球市场上有着稳固的地位。朗盛的核心业务包括生产、开发及销售化学中间体产品、添加剂、特殊化学品与塑料。2005年1月31日，朗盛股票首次在法兰克福证券交易所挂牌上市，朗盛化学（中国）有限公司正式成立。 国内主要产能 中国国内目前产量约7.5万卤水提溴和海水提溴，不包含回收氢溴酸和溴化盐二次提溴，其中以山东地区的地下卤水为原料利用空气吹出法生产的溴素占全国溴素生产量的90%以上，剩余的部分则是以海水制盐过程中的中度卤水为原料采用空气吹出法或水蒸气蒸馏法进行生产，初步统计国内溴使用需求量15多万吨，年进口量约6万吨。 （国内主产区溴素产量分布图） 其他，在辽宁营口，山西运城还有部分产量；四川的邛崃和遂宁周边地区、青海湖也有溴资源，但缺乏开采技术，开采有限和未开采。 需要补充的是，中国从卤水中提取溴的含量已经比较低了，因此国内目前也有许多企业去印度和埃塞俄比亚生产溴素，因为那块资源较多，具有较多机会。 同花顺财经显示，2020年全年溴素进口量5.39万吨，受疫情影响，与2019年相比环比减少10%。不过随着国内地下卤水逐年减少，海水溴大规模生产未取得大突破之前，未来对进口溴的需求有增无减。 “2020年国内进口溴素仍多集中于山东、江苏、浙江、上海和广东，这与下游消费集中地相吻合。其中，山东地区溴素进口量达3.29万吨，环比下滑11.7%，占全年进口量的53.9%，其中潍坊是全国最大的盐溴生产和出口基地，“蓝色”基础较好，原盐、纯碱、溴素产量分别占全国1/4、1/6、9/10；江苏地区溴素进口量2.9万吨，环比下滑6.8%，占全年进口量的17.1%；浙江地区溴素进口量0.92万吨，环比下滑29.1%，占全年进口量的12.1%；上海地区溴素进口量0.58万吨，环比增长14.7%，占全年进口量的12.3%。” 国内主要生产厂家部分企业介绍及产品 山东邦奥化工有限公司 山东邦奥化工有限公司位于渤海莱州湾畔，主要生产经营溴素、氢溴酸、溴化钠等溴化物产品，公司所销售的溴化钠、氢溴酸等产品，不仅出口中东和东南亚地区，还内销至许多省份。产品在油田钻井的完井液的配制、医药中间体、农药生产、AC发泡、丁氰生产、日用化工等多领域中广泛使用，为了产品质量，公司建立了溴化物生产工厂，所生产的溴化物均采用酸碱中和法合成生产工艺，从而实现了产品质量的稳定性和纯度。 山东海化集团 山东海化集团有限公司是潍坊市属国有大型企业集团，1995年8月由原潍坊纯碱厂和山东羊口盐场两个国有大（一）型企业跨行业联合组建而成。1998年5月，山东海化股份有限公司在深交所上市。占地面积128平方公里，注册资本7.24亿元，是全国重要的海洋化工生产和出口基地、国内盐化工龙头企业。 山东裕源集团有限公司 山东裕源集团有限公司位于山东潍坊滨海经济技术开发区，公司从事工业溴、工业盐、H酸、硫酸、聚乙烯管材和渔业网具等产品的生产和销售，同时也从事房地产开发、建筑安装、筑路桥梁、农场养殖、远洋运输、经贸、物流、金融和酒店运营等产业的开发和运营。公司拥有溴素厂六处，主导产品工业溴，年生产能力16000吨左右，是全国重要的工业溴生产基地。 山东诚源集团 山东诚源集团位于莱州市，于2004年9月注册成立，现有原盐、溴化工、陆海物流、绿色新能源、银海工业园、金融战略投资、海洋牧场和海上粮仓、国家级休闲渔业示范基地、蓝色海岸带田园综合体（中观种业硅谷）以及配套科研机构等全球十大业务板块。拥有职工3000多人，年产优质原盐160万吨，溴素1.2万吨。莱州卤水资源丰富，先进环保的卤水制溴工艺，使集团年产优质溴素12000吨，成为中国化工基础原料的重出地。  山东兄弟科技 山东兄弟科技股份有限公司位于山东省寿光市渤海工业园区内，占地面积298亩，是一家以海洋化工产品-----溴系列阻燃剂以及医药中间体为主导，集科、工、贸为一体的成长型精细化工企业。始建于1996年成立的寿光市海洋化工有限公司，专注于溴系阻燃剂和药物中间体的研发制造。现已生产开发的产品有四溴双酚A、八溴醚、溴化聚苯乙烯、三溴苯酚、四溴醚、聚二溴苯醚、三(三溴苯基)三嗪、八溴双酚S醚以及医药中间体IVA等十余个品种，其中四溴双酚A和八溴醚产量和质量均居全国之首，公司也成为目前国内阻燃界单品种规模大、产品种类较多、创新能力极强的阻燃剂研发和生产型企业。 结   语 随着近几年溴素价格一直保持高位，由它衍生出种类繁多的无机溴化物、溴酸盐和舍溴有机化合物，它们在国民经济和科技发展中占据越来越重要的地位，随着各国主导工业的发展，逐渐渗透到各个行业和领域之中。 平常我们看到将溴用作阻燃剂比较多，用到医药农药这块相对比较少，现在也有将溴运用在石油开采的。 关于发展溴产业，在这里提醒大家一句，如果在海外掌握了一个非常好的资源，将其往下衍生就有好的产业链，这种战略性的资源产品可以将他源头抓住随后往下游衍生会产生非常大的效果。 除了溴，还想了解更多？扫码关注“药鼎记”视频号，学习不迷路，随时分享行业各类信息。 参考： https://wenku.baidu.com/view/07fb2034a36925c52cc58bd63186bceb19e8eddf.html https://baike.baidu.com/item/%E6%B6%B2%E6%BA%B4/5455021?fr=aladdin http://www.100ppi.com/data/detail-20210321-1000676.html http://www.100ppi.com/data/detail-20210321-1000675.html http://www.100ppi.com/data/detail-20210321-1000719.html http://goodsfu.10jqka.com.cn/20210207/c626898253.shtml https://wenku.baidu.com/view/d888ea39fd0a79563c1e72c8.html https://wenku.baidu.com/view/fbbe7a7126fff705cd170a39.html 药融云数据，www.pharnexcloud.com； FDA/EMA/PMDA； 相关公司官网； 相关公司公开披露；等等。 【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。 点分享 点点赞点在看